Key Articles and Guidelines in the Management of Heart Failure: 2018 Update

Abstract

Heart failure is one of the leading causes of hospitalizations in the United States, with >1 million admissions yearly and a 25% risk of readmissions within 1 month. In order to assist clinicians, we provide an update of the heart failure bibliography that was published in Pharmacotherapy in 2008, which followed the original bibliography published in 2004. A significant number of clinical trials and observational studies have been conducted since the early 1980s to guide management of heart failure patients. Major advances have occurred in the past 10 years, and our understanding of the diagnosis, prevention, and management of heart failure has evolved substantially during this time period. Specific areas of this review include heart failure risk factors, management of comorbid conditions, acute heart failure management, chronic heart failure management, advanced heart failure, device therapy, lifestyle modification, and medication and therapy management, including medication adherence. Key consensus guidelines and statements are also included. This bibliography of key heart failure papers aims to provide clinicians and their trainees with a valuable clinical reference resource and teaching tool that may be used to optimize the care of patients with heart failure.

Relationship between disorders of the intestinal microbiota and heart failure in infants with congenital heart disease

“…Heart failure is a formidable global public health challenge and is responsible for more than 1 million hospitalisations each year (Jackevicius et al, 2019). Heart failure describes a variety of cardiac structural or functional diseases that result in impaired ventricular filling or ejection capacity, insufficient blood perfusion in organs and tissues, and pulmonary or systemic circulation stasis (Jia et al, 2019).…”

Impact of diastolic dysfunction on outcome in heart failure patients with mid‐range or reduced ejection fraction

“…2 The overall incidence of HF has been estimated to be 100-500 per 100 000 persons at risk in the general population, based on data from European countries and the USA. [3][4][5] Despite recent substantial improvements in medical care, 6 the outcome related with HF remains generally ominous. A recent systematic review and meta-analysis summarized survival data from 1.5 million patients with chronic HF across 60 studies; it was reported that the pooled survival rates at 1 month, 1, 2, 5, and 10 years were 65.7%, 86.5%, 72.6%, 56.7%, and 34.9%, respectively.…”